

Acute and Chronic Inflammation of the Biliary System

Vincent Zimmer^a Matthias Glanemann^b Frank Lammert^a

^aDepartment of Medicine II, Saarland University Medical Center, Homburg/Saar, Germany,

^bDepartment of General, Visceral, Vascular and Pediatric Surgery, Saarland University Medical Center, Homburg/Saar, Germany

Acute and chronic inflammatory biliary tract disease has ever since been in the vanguard of gastrointestinal medicine at the interface between surgical and medical care. Likewise, biliary system disorders demand the cooperation between high-volume specialized and community-based patient care, ranging from standard cholecystectomy over personalized assessment of bile duct strictures to liver transplantation for chronic cholestatic liver diseases. In this sense, inflammatory biliary diseases represent a timeless but vital topic forming the overarching theme of the current edition of VISZERALMEDIZIN to which we as Guest Editors warmly welcome you.

In this issue old acquaintances will be revisited and new ones be met – such as the emerging topic of the biliary mucosal barrier and the microbiome. This fascinating, novel topic, though still in its infancy, will be introduced by Verdier, Luedde and Sellge [1] from Aachen. Contrary to the paradigm of a sterile biliary milieu under healthy conditions, new data suggest a complex commensal colonization as well as specialized defence and tolerance mechanisms within the biliary system. The impact of this biliary mucosal barrier on chronic hepatobiliary diseases has to be substantiated further in the future. Schuld and Glanemann [2], Homburg, present a state-of-the-art update on the management of acute cholecystitis, representing one of the most common emergencies in visceral medicine. In contrast to the die-hards of hard rock still touring around the world, the recent ACDC trial has set a general standard of care with acute cholecystectomy being performed within the first 24 h after hospitalization that has been embraced and specified by interdisciplinary guidelines. Zimmer and Lammert [3] from Homburg present an update on the mostly endoscopic management of acute bacterial cholangitis and put adequate diagnosis including imaging microbiology and timing as well as modalities of biliary drainage into perspective.

Primary sclerosing cholangitis (PSC) as a chronic fibro-obliterative disease of the larger bile ducts is the remaining ‘black box’ of hepatology. For this highly cancer-prone disease of unknown aetiology, there are neither sufficient diagnostic tools nor treatment options available. Reasonable suggestions for patient care by experts in

the field are presented by Ehlken and Schramm [4] from one of the centres providing excellent care for PSC in Hamburg. Remaining in the same topical corner, Kirchner and Ruesmele [5] from Regensburg have pioneered the emerging role of sclerosing cholangitis in critically ill patients (SC-CIP), representing a subgroup of secondary sclerosing cholangitis (SSC). Considering that full-blown SC-CIP tends to be progressive with patients requiring liver transplantation, the characterization of patient populations at particular risk represents a clinically relevant research topic. Besides SCC, immunoglobulin G4-associated cholangiopathy has attracted much attention in recent years. While the chronic inflammatory disease may mimic several biliary or pancreatic cancer as well as PSC, it stands out for its reversibility by anti-inflammatory corticosteroids. Therefore, the diagnosis of this disease is critical, and strategies as well as new tools are presented by Hubers and Beuers [6] from Amsterdam.

Coming to the last two contributions, the surgeons enter the arena with Bartsch, Heinrich and Lang [7] from Mainz discussing the current limits of surgical resection for bile duct cancer. This topic is critical given the fact that these patients present at a later stage and higher age with comorbidities. Notwithstanding these intricacies, the assessment of resectability of bile duct cancer should be performed by highly specialized hepatobiliary surgeons and communicated with confidence to improve the outcomes for this highly difficult-to-treat tumour. Last but not least, Neumann and colleagues [8], Aachen, discuss the current status of liver transplantation for patients suffering from cholestatic liver diseases. Although this topic has come a long way from being one of the most common indications for liver transplantation two decades ago to a less common one nowadays, controversial issues still remain, in particular related to organ allocation, surgical reconstruction, and disease recurrence.

At this stage, we believe that we might have come full circle by now from community to centre and from surgery to gastrointestinal medicine and vice versa. In this sense, we hope that all of you find novel ideas and clinical concepts for your day-to-day care of patients suffering from acute or chronic inflammatory diseases of the biliary system.

References

- 1 Verdier J, Lüdde T, Sellge G: Biliary mucosal barrier and microbiome. *Viszeralmedizin* 2015;31:156–161.
- 2 Schulz J, Glanemann M: Acute cholecystitis. *Viszeralmedizin* 2015;31:163–165.
- 3 Zimmer V, Lammert F: Acute bacterial cholangitis. *Viszeralmedizin* 2015;31:166–172.
- 4 Ehlken H, Schramm C: How should cancer surveillance in primary sclerosing cholangitis be performed? *Viszeralmedizin* 2015;31:173–177.
- 5 Kirchner GI, Ruemmele P: Update on sclerosing cholangitis in critically ill patients. *Viszeralmedizin* 2015; 31:178–184.
- 6 Hubers LM, Beuers U: How to diagnose immunoglobulin G4-associated cholangitis: the jack-of-all-trades in the biliary tract. *Viszeralmedizin* 2015;31:185–188.
- 7 Bartsch F, Heinrich S, Lang H: Limits of surgical resection for bile duct cancer. *Viszeralmedizin* 2015;31: 189–193.
- 8 Schöning W, Schmeding M, Ulmer F, Andert A, Neumann U: Liver transplantation for patients with cholestatic liver diseases. *Viszeralmedizin* 2015;31:194–198.

Imprint

ISSN Print Edition: 1662-6664

ISSN Online Edition: 1662-6672

Journal Homepage: <http://www.karger.com/vim>

Publication Data: Volume 31, 2015 of 'VISZERALMEDIZIN' appears with 6 issues.

Copyright: © 2015 by S. Karger Verlag für Medizin und Naturwissenschaften GmbH, Freiburg (Germany). All rights reserved. No part of the journal may be reproduced in any form without the written permission of the publisher. This includes digitalisation and any further electronic computing, like saving, copying, printing or electronic transmission of digitalized material from this journal (online or offline). Authorization to photocopy items for internal or personal use of specific clients is granted by Karger.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923 (USA).

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger GmbH, Wilhelmstraße 20A, 79098 Freiburg (Germany).

Disclaimer: The statements and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Distribution and Subscription: Karger offers three types of subscription: Print Only, Online Only and the combined Print + Online. The basic annual subscription rate is the same for all three delivery forms; however, a fee for the combined print and online subscription is levied, and there is a postage and handling charge for Print Only and Print + Online. Subscriptions run for a full calendar year. Prices are given per volume.

Print subscription: EUR 197.- + postage and handling.

Online subscription: EUR 197.-.

Combined (print + online) subscription: EUR 247.- + postage and handling.

For customers in Germany: Please turn to your bookshop or to S. Karger Verlag für Medizin und Naturwissenschaften GmbH Wilhelmstr. 20A, 79098 Freiburg (Germany)
Tel. +49 761 45 20 70, Fax +49 761 45 20 714
E-mail information@karger.com

For customers in all other countries: Please contact your bookshop or S. Karger AG, Allschwilerstr. 10, 4009 Basel (Switzerland)
Tel. +41 61 3 06 11 11, Fax +41 61 3 06 12 34
E-mail karger@karger.com

Advertising: Correspondence should be addressed to the publisher. S. Karger Verlag für Medizin und Naturwissenschaften GmbH Attn. Ellen Zimmermann (Head of Marketing)
E-mail e.zimmermann@karger.com

Price list No. 22 of January 1, 2015 is effective.

V.i.S.d.P. (Person responsible according to the German Press Law): Sibylle Gross

Type setting and printing: Kraft Druck GmbH, 76275 Ettlingen, Germany.

Bibliographic Services:

EMBASE / Excerpta Medica

Reference Update

Science Citation Index Expanded

ISBN 978-3-318-03039-6

e-ISBN 978-3-318-03040-2

KARGER

Fax +49 761 4 52 07 14
Information@Karger.com
www.karger.com

© 2015 S. Karger GmbH, Freiburg

Accessible online at:
www.karger.com/vim